ENDO 2021: Rhythm Pharma Phase 2 Data on Continued Weight Loss on Setmelanotide

 -- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy --

-- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events in Phase 2 and Phase 3 studies in POMC, PCSK1, or LEPR deficiency showing consistent safety results for setmelanotide --

https://www.globenewswire.com/news-release/2021/03/20/2196506/0/en/Rhythm-Pharmaceuticals-Presents-New-Data-from-Phase-2-Basket-Study-Showing-Continued-Weight-Loss-at-Up-to-Nine-Months-in-Patients-with-HET-Obesity-on-Setmelanotide-at-ENDO-2021.html